Enwave Corporation Stock
?
Your prediction
Enwave Corporation Stock
Pros and Cons of Enwave Corporation in the next few years
Pros
Cons
Performance of Enwave Corporation vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Enwave Corporation | -7.770% | -5.641% | -13.208% | 6.977% | -22.034% | -11.962% | -79.935% |
| Aurinia Pharmaceuticals Inc. | 0.690% | 4.180% | 2.400% | 63.697% | -6.570% | 62.157% | 5.050% |
| Spectral Medical Inc | -1.780% | 8.333% | 8.333% | 101.190% | 6.289% | 294.860% | 97.430% |
| Fennec Pharmaceuticals Inc. | -2.680% | 0.685% | 13.953% | 14.844% | 14.844% | -10.366% | 14.844% |
News
EnWave Reports 2026 First Quarter Consolidated Interim Financial Results
Vancouver, B.C., February 20th, 2026. EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the "Company") today reported the Company’s consolidated interim financial results for the first
EnWave Signs Royalty-Bearing License with Bowen Gumlu Grower’s Association of Australia
Vancouver, B.C., February 2nd, 2026, EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the "Company") today announced that the Company has signed a royalty-bearing commercial license
EnWave Reports 2025 Fourth Quarter and Annual 2025 Consolidated Financial Results
Vancouver, B.C., December 15th, 2025 / EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the "Company") today reported the Company’s consolidated interim financial results for the fourth

